1. Home
  2. VATE vs PMVP Comparison

VATE vs PMVP Comparison

Compare VATE & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

HOLD

Current Price

$15.22

Market Cap

168.2M

Sector

Industrials

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.19

Market Cap

76.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VATE
PMVP
Founded
1994
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
168.2M
76.8M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
VATE
PMVP
Price
$15.22
$1.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
55.7K
380.1K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,246,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.55
N/A
52 Week Low
$3.75
$0.85
52 Week High
$16.71
$1.88

Technical Indicators

Market Signals
Indicator
VATE
PMVP
Relative Strength Index (RSI) 67.02 33.69
Support Level $4.48 $1.09
Resistance Level N/A $1.26
Average True Range (ATR) 1.23 0.08
MACD 0.19 -0.02
Stochastic Oscillator 78.77 3.31

Price Performance

Historical Comparison
VATE
PMVP

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: